In Brief: Schwarz/Axcan Urso
Schwarz/Axcan Urso: Potential market for Urso is $70 mil. annually two years after approval based on 12% market growth and percentage penetration. Total annual market for primary biliary cirrhosis is $100 mil. based on patient population of 50,000; the remaining 30% of the market consists of untreated patients or those receiving off-label drugs ("The Pink Sheet" Dec. 15, 1997, T&G-5)...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth